These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31350794)

  • 1. The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia.
    Zheng G; Chen P; Pallavajjalla A; Haley L; Gondek L; Dezern A; Ling H; De Marchi F; Lin MT; Gocke C
    Am J Hematol; 2019 Oct; 94(10):1141-1148. PubMed ID: 31350794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow Cytometric Findings in Clonal Cytopenia of Undetermined Significance.
    Nirmalanantham P; Sakhi R; Beck R; Oduro K; Gadde R; Ryder C; Yoest J; Sadri N; Meyerson HJ
    Am J Clin Pathol; 2022 Feb; 157(2):219-230. PubMed ID: 34542558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.
    Liu L; Zhang D; Fu Q; Wang J; Yu J; Chen D; Wang F; Guo R; Xie X; Jiang Z; Li Y
    Clin Exp Med; 2023 Dec; 23(8):4473-4482. PubMed ID: 37087521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience.
    Gao L; Hyter S; Zhang D; Kelting S; Woodroof J; Abdallah AO; Yacoub A; McGuirk J; Abdelhakim H; Godwin AK; Cui W
    Int J Lab Hematol; 2022 Aug; 44(4):738-749. PubMed ID: 35352484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS-type molecular findings compared to CCUS without dysplasia.
    Jajosky AN; Sadri N; Meyerson HJ; Oduro KA; Kelkar A; Fitzgerald B; Tomlinson B; Moore EM; Beck RC
    Eur J Haematol; 2021 Apr; 106(4):500-507. PubMed ID: 33386622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
    Bartels S; Schipper E; Hasemeier B; Kreipe H; Lehmann U
    Oncotarget; 2016 May; 7(21):30084-93. PubMed ID: 27029036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.
    Kwok B; Hall JM; Witte JS; Xu Y; Reddy P; Lin K; Flamholz R; Dabbas B; Yung A; Al-Hafidh J; Balmert E; Vaupel C; El Hader C; McGinniss MJ; Nahas SA; Kines J; Bejar R
    Blood; 2015 Nov; 126(21):2355-61. PubMed ID: 26429975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
    Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
    Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.
    Cargo C; Bernard E; Beinortas T; Bolton KL; Glover P; Warren H; Payne D; Ali R; Khan A; Short M; Van Hoppe S; Smith A; Taylor J; Evans P; Papaemmanuil E; Crouch S
    Lancet Haematol; 2024 Jan; 11(1):e51-e61. PubMed ID: 38135373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia.
    Lew JL; Fenderson JL; Carmichael MG
    Hawaii J Med Public Health; 2017 Nov; 76(11 Suppl 2):10-12. PubMed ID: 29164009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
    Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
    Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
    Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.
    Ferrone CK; McNaughton AJM; Rashedi I; Ring B; Buckstein R; Tsui H; Rauh MJ
    Mod Pathol; 2023 Mar; 36(3):100068. PubMed ID: 36788103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
    Bejar R
    Curr Hematol Malig Rep; 2015 Sep; 10(3):282-91. PubMed ID: 26126599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
    Cremers EMP; Westers TM; Alhan C; Cali C; Wondergem MJ; Poddighe PJ; Ossenkoppele GJ; van de Loosdrecht AA
    Eur J Cancer; 2016 Feb; 54():49-56. PubMed ID: 26720403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome.
    Choi EJ; Cho YU; Hur EH; Park HS; Choi Y; Lee JH; Lee KH; Kim M; Hwang SH; Jang S; Park CJ; Seo EJ; Lee JH
    Br J Haematol; 2022 Aug; 198(4):703-712. PubMed ID: 35612271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic analysis of Chinese patients with clonal cytopenias using targeted next-generation sequencing.
    Zhang L; Shi Y; Chen Y; Tao S; Shi W; He Z; Chen K; Wang C; Yu L
    Mol Cytogenet; 2021 Nov; 14(1):52. PubMed ID: 34794475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.